Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy tested to keep lung cancer at bay

NCT ID NCT01186861

Completed Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

Summary

This study tested whether adding an experimental drug called OSI-906 to an existing lung cancer drug (erlotinib) could help keep advanced lung cancer from getting worse for a longer time. It involved 205 adults whose cancer had not progressed after four rounds of standard chemotherapy. The main goal was to see if the two-drug combination was better at delaying cancer progression than erlotinib alone.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) WITH NONPROGRESSION FOLLOWING 4 CYCLES OF PLATINUM-BASED CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Site BR55001

    Itajaí, 88301-220, Brazil

  • Site BR55002

    Rio de Janeiro, 20231-050, Brazil

  • Site BR55003

    Fortaleza, 60336-550, Brazil

  • Site BR55004

    Brasília, 70840-050, Brazil

  • Site BR55005

    Barretos, 14784-400, Brazil

  • Site BR55006

    Ijuí, 98700-000, Brazil

  • Site BR55007

    São Paulo, 01323-920, Brazil

  • Site BR55008

    Piracicaba, 13419-155, Brazil

  • Site BR55011

    Florianópolis, 88034-000, Brazil

  • Site BR55012

    Ribeirão Preto, 14515-130, Brazil

  • Site BR55013

    Porto Alegre, 90430-090, Brazil

  • Site BR55014

    Porto Alegre, 90610-000, Brazil

  • Site BR55015

    Cachoeiro de Itapemirim, 29308-014, Brazil

  • Site BR55016

    Goiânia, 74605-030, Brazil

  • Site CA11001

    Oshawa, L1G 2B9, Canada

  • Site CA11002

    Toronto, M6R 1B5, Canada

  • Site CA11004

    Ottawa, K1H 8L6, Canada

  • Site CA11006

    Toronto, M5G 1X5, Canada

  • Site DE49001

    Heidelberg, 69126, Germany

  • Site DE49002

    Hemer, 58675, Germany

  • Site DE49003

    Großhansdorf, 22977, Germany

  • Site DE49005

    Minden, 32429, Germany

  • Site DE49006

    Immenhausen, 34376, Germany

  • Site DE49008

    Cologne, 51109, Germany

  • Site DE49009

    Homburg/Saar, 66421, Germany

  • Site DE49010

    Lübeck, 23538, Germany

  • Site DE49011

    Dortmund, 44145, Germany

  • Site DE49012

    Karlsruhe, 76137, Germany

  • Site DE49013

    Mainz, 55131, Germany

  • Site DE49014

    Berlin, 10117, Germany

  • Site DE49015

    Kassel, 34125, Germany

  • Site GB44001

    Manchester, M20 4BX, United Kingdom

  • Site GB44002

    Leicester, LE1 5WW, United Kingdom

  • Site GB44003

    Leeds, LS9 7TF, United Kingdom

  • Site GB44004

    Southampton, SO16 6YD, United Kingdom

  • Site GB44005

    London, NW1 2PQ, United Kingdom

  • Site GB44006

    Dundee, DD1 9SY, United Kingdom

  • Site GB44007

    Bristol, BS2 8ED, United Kingdom

  • Site KR82001

    Suwon, South Korea

  • Site KR82002

    Seoul, 137-701, South Korea

  • Site KR82003

    Seoul, 120-752, South Korea

  • Site KR82004

    Seongnam-si, 463-707, South Korea

  • Site KR82005

    Seoul, 135-710, South Korea

  • Site KR82006

    Hwasun, 519-809, South Korea

  • Site KR82007

    Busan, 602-715, South Korea

  • Site KR82008

    Incheon, 400-711, South Korea

  • Site PL48002

    Elblag, 82-300, Poland

  • Site PL48005

    Szczecin, 70-891, Poland

  • Site PL48006

    Wroclaw, 53-439, Poland

  • Site PL48008

    Torun, 87-100, Poland

  • Site RO40001

    Baia Mare, 490110, Romania

  • Site RO40002

    Cluj-Napoca, 400015, Romania

  • Site RO40003

    Cluj-Napoca, 400015, Romania

  • Site RO40004

    Hunedoara, 331057, Romania

  • Site RO40005

    Alba Iulia, 510077, Romania

  • Site RO40006

    Craiova, 200535, Romania

  • Site RO40007

    Brasov, 500366, Romania

  • Site RU70002

    Chelaybinsk, 454087, Russia

  • Site RU70007

    Saint Petersburg, 194291, Russia

  • Site RU70009

    Saint Petersburg, 197089, Russia

  • Site RU70010

    Kazan', 420029, Russia

  • Site RU70011

    Saint Petersburg, 197089, Russia

  • Site US10001

    Port Saint Lucie, Florida, 34952, United States

  • Site US10002

    Albany, Georgia, 31701, United States

  • Site US10004

    Greensboro, North Carolina, 27403, United States

  • Site US10007

    Jacksonville, Florida, 32207, United States

  • Site US10008

    Chicago, Illinois, 60612, United States

  • Site US10010

    Winston-Salem, North Carolina, 27103, United States

  • Site US10011

    Scarborough, Maine, 04074, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER (NSCLC) WITH NONPROGRESSION FOLLOWING 4 CYCLES OF PLATINUM-BASED CHEMOTHERAPY